7,085 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Persistent Asset Partners Ltd

Persistent Asset Partners Ltd acquired a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 7,085 shares of the company’s stock, valued at approximately $674,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Viking Global Investors LP acquired a new stake in Oruka Therapeutics in the third quarter valued at approximately $51,280,000. Deep Track Capital LP increased its position in shares of Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after purchasing an additional 735,983 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Oruka Therapeutics by 38.1% during the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after purchasing an additional 676,865 shares during the last quarter. RTW Investments LP lifted its holdings in shares of Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after purchasing an additional 112,499 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP purchased a new stake in shares of Oruka Therapeutics during the 4th quarter valued at $51,840,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ORKA. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, April 30th. HC Wainwright reiterated a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research note on Monday, August 3rd. UBS Group raised their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Barclays boosted their price target on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research note on Monday, April 27th. Finally, BTIG Research restated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $134.30.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $111.04 on Monday. The firm has a market capitalization of $7.35 billion, a price-to-earnings ratio of -54.70 and a beta of -0.34. The business has a fifty day moving average of $87.52 and a 200 day moving average of $62.81. Oruka Therapeutics, Inc. has a 1 year low of $14.08 and a 1 year high of $111.37.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, equities research analysts expect that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In related news, Director Carl Dambkowski sold 12,583 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $70.11, for a total value of $882,194.13. Following the sale, the director owned 38,743 shares in the company, valued at $2,716,271.73. This represents a 24.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the completion of the transaction, the chief executive officer owned 925,580 shares in the company, valued at approximately $64,503,670.20. This trade represents a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 181,116 shares of company stock worth $12,045,503. 23.49% of the stock is owned by company insiders.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.